David Hepworth

机构：Pfizer (United States), Cellucomp (United Kingdom), University of Cumbria · ORCID：0009-0009-6787-4662

发表论文 116 篇 · 总被引 5630 次 · h-index 37

代表论文

• Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay (2017 · PLoS ONE · 被引 167)
• Discovery of Clinical Candidate 1-{[(2 S ,3 S ,4 S )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design (2017 · Journal of Medicinal Chemistry · 被引 150)
• The RESOLUTE consortium: unlocking SLC transporters for drug discovery (2020 · Nature Reviews Drug Discovery · 被引 110)
• Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells (2024 · Science · 被引 95)
• Postoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial (2021 · The Lancet Respiratory Medicine · 被引 60)
• Nanofibers Produced from Agro-Industrial Plant Waste Using Entirely Enzymatic Pretreatments (2018 · Biomacromolecules · 被引 40)